Filing Flows › Editas Medicine (EDIT) › Q1 2026
Editas Medicine (EDIT) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 5, 2026
Editas Medicine (EDIT) reported revenue of $2.8M for the first quarter 2026 (Q1 2026), -39% from a year earlier and -89% from the quarter before. Operating margin was -883.2%, net loss $25.0M (882.4% of revenue).
Editas Medicine, Q1 2026: revenue $2.8M (-39% year over year), operating margin -883.2%, net loss $25.0M, operating cash flow −$23.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.8M | -89% | -39% |
| Operating profit | −$25.0M | — | — |
| Net earnings | −$25.0M | — | — |
| Operating cash flow | −$23.1M | — | — |
What changed
Revenue was $2.8M in Q1 2026, down 39% year over year and down 89% from the previous quarter.
Operating costs exceeded revenue by $25.0M, an operating margin of -883.2%. Total costs fell 66% while revenue fell 39%. The quarter ended with a net loss of $25.0M, wider than the previous quarter's $5.6M loss.
Operating cash flow was −$23.1M. Non-cash charges added back $483K of depreciation and $2.1M of share-based compensation. Capital expenditures of $92K exceeded it, leaving free cash flow of −$23.2M.
Questions
What was Editas Medicine's revenue in the first quarter 2026?
Editas Medicine (EDIT) reported revenue of $2.8M for the first quarter 2026 (Q1 2026), -39% from a year earlier and -89% from the quarter before.
Was Editas Medicine profitable in the first quarter 2026?
Operating loss was $25.0M (-883.2% of revenue) and net loss $25.0M.
Source: Editas Medicine 10-Q on SEC EDGAR.